Industry: Healthcare
Published Date: March-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 278
Report ID: PMRREP25768
The global oral solid dosage contract manufacturing market reached a value of US$ 23.4 Bn in 2021, and is predicted to expand at a CAGR of 5.9% to climb to a valuation of US$ 43.6 Bn by the end of 2032.
| Attribute | Key Insights |
|---|---|
|
Market Size (2021) |
US$ 23.4 Bn |
|
Estimated Market Value (2022) |
US$ 24.7 Bn |
|
Projected Market Value (2032) |
US$ 43.6 Bn |
|
Global Market Growth Rate (2022-2032) |
5.9% CAGR |
|
Market Share of Top 5 Countries |
46.6% |
As projected by Persistence Market Research, the immediate-release mechanism accounted for a market value of US$ 12.5 Bn, which was more than 50% share of the market in 2021.
In 2021, the oral solid dosage contract manufacturing revenue accounted for approx. 12% share of the global contract manufacturing market, mainly due to increasing R&D activities to develop novel technologies in the formulation of oral solid dosage forms and rise in long-term contract manufacturing partnerships between biotechnology companies and CDMOs.
The global oral solid dosage contract manufacturing market expanded at a CAGR of 4.5% over the last five years (2017-2021).
Rising incidence of viral and chronic diseases has driven demand for new therapeutics to secure and cure the affected population across the world. Pharmaceutical products are treatments or therapies generated from metabolites that occur naturally in living forms. High use of pharmaceutical drugs by patients suffering from a variety of diseases has created the dire need for the large-scale manufacture of novel therapeutics.
With increased demand for large-scale production, major pharmaceutical companies are increasingly outsourcing contract manufacturing. As a result, the need for oral solid dosage contract manufacturing will increase as demand for novel therapies grows.
Furthermore, rising economic prosperity and increased health awareness are also likely to boost market development in the years ahead.
Companies nowadays are concentrating on acquiring and merging with others in order to expand their market share and capitalize on shared technology. Manufacturing costs are rising all the time. As a result, both large and small pharma and biotech businesses are concentrating their efforts on CDMOs in order to form long-term contract manufacturing agreements. This will assist enterprises in sticking to fixed manufacturing rates and CDMOs in improving manufacturing quality.
The global market for oral solid dosage contract manufacturing is expected to expand at a CAGR of 5.9% and record sales worth US$ 43.6 Bn by 2032.
“Technological Advances in Oral Solid Dosage Forms”
The forecast period is set to witness many lucrative opportunities for oral solid dosage contract manufacturing companies around the world. These companies can concentrate on technological advancements in oral solid dosage forms to improve their stability, yield, bioavailability, and morphological characteristics, as well as to develop various types of oral solid dosage forms such as enteric-coated, extended-release, controlled release, and others.
Despite these developments, there are still many shortcomings, such as the market is still divided and has many small CMOs, and due to this, there is no prime provider of pharmaceutical solid dose contract manufacturing. This provides significant opportunity for consolidation, which can aid companies with better operating margins and high potential for faster growth in the market.
Furthermore, contract development and manufacturing firms can concentrate on creating adaptable business models. A flexible business model will lure both, large and small pharma and biotech firms.
The particle engineering technique is used by many CDMOs to create oral solid dose forms. CDMOs may be able to expand their market share by acquiring this technology.
“Strict Approval Criteria by Regulatory Authorities”
Every country has a significant number of regulations that are laid down by regulatory authorities. Furthermore, tiny CDMOs, without cutting-edge equipment, are more prone to see increasing process errors, poor quality, and pricing issues.
As a result of the rigorous rules imposed by regulatory agencies, there has been a decrease in the approval of small molecules in developed countries, which has hampered demand growth of contract development and manufacturing.
Several small and major CDMOs use a variety of techniques to gain market strength, including manufacturing growth, collaborations, partnerships, and acquisitions.
Because the cost of development in poor countries is lower than in developed countries, most pharma and biotech corporations award contracts to CDMOs in these countries. Language hurdles, cultural differences, and different time zones can all slow down the communication process and cause delays in product delivery.
Why is Oral Solid Dosage Contract Manufacturing Huge in the U.S.?
“Advanced Healthcare Sector in the U.S.”
In 2021, the U.S. accounted for 83.4% share in North America oral solid dosage contract manufacturing market due to the expansion of manufacturing facilities and growing emphasis on drug discovery.
Additionally, ongoing advancements in the pharmaceutical sector and increasing demand for superior quality products place a strong emphasis on drug research, and, as a result, growing number of pharmaceutical businesses are turning to CMOs in the U.S.
Why is China Emerging as a Prominent Market for Oral Solid Dosage Contract Manufacturing?
“Cost-effectiveness - Key Driver for Market in China”
The China market for oral solid dosage contract manufacturing accounted for more than 50% of the market share in East Asia in 2021. The market in China was recorded to be worth US$ 1.9 Bn in 2021.
Outsourcing of pharmaceutical manufacturing is developing the fastest in Asia. Chinese CMOs have emerged as ideal outsourcing partners for a variety of reasons.
Improved regulatory oversight and adherence to CGMP standards, skilled Chinese workforce, and cost containment are some of the key factors that will positively drive the growth of this industry in China over the coming years.
Which Dosage Form Accounts for Highest Market Growth?
“Tablet Dosage Form Accounts for Major Market Share”
The tablet form is driving most demand in this market, wherein, it accounted for approx. 34% market share by product in oral solid dosage contract manufacturing in the year 2021.
Tablets are non-invasive and have the ability to pass the first pass metabolism. Increasing demand for tablets as compared to capsules and powder is the primary factor contributing toward this high segment share across regions
Which Mechanism is Mostly Adopted by Oral Solid Dose Contract Manufacturers?
“Immediate-release Mechanism Most Popular”
The immediate-release mechanism is most commonly adopted by oral solid dose manufacturers. The immediate-release mechanism holds a market share of 53.7% by value, in the global oral solid dosage contract manufacturing market, and is expected to expand at a CAGR of 5.6% over the forecast period.
High segment growth is due to the fact that immediate-release tablets work by quickly relieving pain and discomfort, and they also have the ability to provide advantages of liquid medication in the form of solid preparation.
The COVID-19 pandemic and lockdowns across the globe affected most industries. The healthcare industry experienced extreme ups and downs during these lockdown periods. Most pharmaceutical and biotechnological industries experienced both, positive and negative trends during the pandemic.
The healthcare sector across the globe witnessed major changes during this time. Approval of many oral solid dosage forms pertaining to treatment of viral infections was given preference, and this led to overall growth of the oral solid dosage contract manufacturing industry.
Demand for pharmaceutical manufacturing is increasing day by day, and therefore, companies are focusing on the expansion of their manufacturing units.
Additionally, key providers of oral solid dosage contract manufacturing products have adopted the strategies of acquisitions and expansions as a part of their efforts to consolidate their market presence.
| Attribute | Details |
|---|---|
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2017-2021 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
By Dosage Form:
By Mechanism:
By Application:
By End User:
By Region:
To know more about delivery timeline for this report Contact Sales
The global oral solid dosage contract manufacturing market is currently valued at US$ 23.4 Bn, and is expected to grow 1.8X by 2032.
Oral solid dosage contract manufacturing demand is set to witness a high growth rate of 5.9% and be valued at US$ 43.6 Bn by 2032.
The market for oral solid dosage contract manufacturing expanded at 4.5% CAGR from 2017 through 2021.
Key players are opting for regulatory approvals, increasing demand for long-term contract manufacturing partnerships, manufacturing expansion, and key players focusing on emerging markets for the development of novel technologies are key trends shaping the industry.
The tablet form of dosage is driving most demand and accounted for approx. 34.1% market share in 2021.
The U.S., China, Japan, Germany, and Australia are expected to drive high demand growth of oral solid dosage contract manufacturing products.
The North America oral solid dosage contract manufacturing market accounted for more 25.2% of the market share in 2021.
The Europe market for oral solid dosage contract manufacturing is expected to record a CAGR of 5.3% over the forecast period, amongst which, Germany accounted for the highest share of 24.3% in 2021.
The U.S., Japan, and China are key providers of oral solid dosage contract manufacturing.
The China market is expected to expand at a CAGR of 6.9%, while Japan accounted for 36.5% share of the East Asia market in 2021.
